Similar articles

• Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.

  Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Dierickx D, et al. Am J Hematol. 2011 Mar;86(3):278-91. doi: 10.1002/ajh.21939. Epub 2011 Feb 15. Am J Hematol. 2011. PMID: 21328427 Review.
• Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

  Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S. Rao A, et al. Pediatr Blood Cancer. 2008 Apr;50(4):822-5. doi: 10.1002/pbc.21264. Pediatr Blood Cancer. 2008. PMID: 17570702 Clinical Trial.
• Rituximab in the treatment of autoimmune haematological disorders.

  Provan D, Newland AC, Amadori S, Stasi R. Provan D, et al. Br J Haematol. 2008 Oct;143(2):294; author reply 295. doi: 10.1111/j.1365-2141.2008.07326.x. Epub 2008 Aug 24. Br J Haematol. 2008. PMID: 18752592 No abstract available.
• The late adverse events of rituximab therapy--rare but there!

  Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. Ram R, et al. Leuk Lymphoma. 2009 Jul;50(7):1083-95. doi: 10.1080/10428190902934944. Leuk Lymphoma. 2009. PMID: 19399690 Review.
• Rituximab in the treatment of autoimmune haematological disorders.

  Garvey B. Garvey B. Br J Haematol. 2008 Apr;141(2):149-69. doi: 10.1111/j.1365-2141.2008.07054.x. Epub 2008 Mar 3. Br J Haematol. 2008. PMID: 18318765 Review.